Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib + pyrotinib + endocrine therapy after prior CDK4/6 inhibitor treatment in HR-positive/HER2-low advanced breast cancer
ChiCTR2300069344Phase 4Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Shantou University Medical College
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dalpiciclib and pyrotinib in breast cancer, sponsored by Affiliated Cancer Hospital of Shantou University Medical College. Primary endpoint: Objective response rate. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
dalpiciclibpyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2300069344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069344.